1

ZAWARTOŚĆ TRANSFORMUJĄCEGO CZYNNIKA WZROSTU – BETA 1 W WARSTWIE PODCHRZĘSTNEJ GŁOWY KOŚCI […]

I Środkowo Europejski Kongres Osteoporozy i Osteoartrozy oraz XIII Zjazd Polskiego Towarzystwa Osteoartrologii i Polskiej Fundacji Osteoporozy, Kraków 6-8.10.2005

Streszczenia:
Ortopedia Traumatologia Rehabilitacja 2005, vol 7 (Suppl. 1), s164.


P37
ZAWARTOŚĆ TRANSFORMUJĄCEGO CZYNNIKA WZROSTU – BETA 1 W WARSTWIE PODCHRZĘSTNEJ GŁOWY KOŚCI UDOWEJ KORELUJE Z NASILENIEM ZMIAN ZWYRODNIENIOWYCH STAWU BIODROWEGO

Zgoda M.,1 Pączek L.,2 Bartłomiejczyk I.,.2 Chmielewski D.,1 Siemińska J.,3 Górecki A.1
1 Katedra i Klinika Ortopedii i Traumatologii Narządu Ruchu Akademii Medycznej w Warszawie; 02-005 Warszawa; ul. Lindleya 4
2 Klinika Immunologii, Transplantologii i Chorób Wewnętrznych Akademii Medycznej w Warszawie
3 Zakład Fizjologii Doświadczalnej i Klinicznej Akademii Medycznej w Warszawie

Słowa kluczowe: choroba zwyrodnieniowa stawu biodrowego; transformujący czynnik wzrostu-beta

Celem pracy była ocena zależności pomiędzy zawartością transformującego czynnika wzrostu-beta 1 (TGF-β1) w warstwie podchrzęstnej głowy kości udowej a stopniem nasilenia zmian zwyrodnieniowych stawu biodrowego w przebiegu choroby zwyrodnieniowej. Do badania włączono 24 pacjentów z chorobą zwyrodnieniową stawu biodrowego. Bioptaty kostne pobrano w czasie operacji endoprotezoplastyki totalnej stawu biodrowego. Oznaczenie zawartości TGF-β1 przeprowadzono z wykorzystaniem metody immunoenzymatycznej ELISA. Stopień nasilenia zmian zwyrodnieniowych stawu biodrowego oceniano z wykorzystaniem klasyfikacji Kellgrena-Lawrence’a, oraz analizując minimalną szerokość szpary stawowej na zdjęciach rentgenowskich.
Zawartość TGF-β1 w przeliczeniu na białko całkowite była wprost proporcjonalna do stopnia nasilenia zmian zwyrodnieniowych. Średnia zawartość TGF-β1 w grupie chorych z najmniej nasilonymi zmianami zwyrodnieniowymi (zakwalifikowanymi do grupy II-giej wg klasyfikacji Kellgrena-Lawrence’a) wynosiła 0,86 pg/μg i była istotnie statystycznie niższa (p0,05) w porównaniu do grupy chorych z największym nasileniem zmiany zwyrodnieniowych (grupa IV), gdzie średnia zawartość TGF-β1 w warstwie podchrzęstnej głowy kości udowej wynosiła 1,72 pg/μg.
Uzyskane wyniki potwierdzają rolę TGF-β1 w etiopatogenezie zmian zwyrodnieniowych stawu biodrowego.


P37
THE CONTENT OF TRANSFORMING GROWTH FACTOR – BETA 1 (TGF-Β1) IN SUBCHONDRAL BONE OF THE FEMORAL HEAD CORRELATES WITH THE SEVERITY OF OSTEOARTHRITIS OF THE HIP

Zgoda M.,1 Pączek L.,2 Bartłomiejczyk I.,2 Chmielewski D.,1 Siemińska J.,3 Górecki A.1
1 Department of Orthopaedics and Traumatology of the Locomotor System; The Medical University of Warsaw
2 Department of Immunology, Transplantology and Internal Medicine; The Medical University of Warsaw
3 Department of Experimental and Clinical Physiology; The Medical University of Warsaw, Poland

Keywords: hip osteoarthritis; transforming growth factor-beta

The aim of the study was to determine the relationship between the content of Transforming Growth Factor-beta 1 (TGF-β1) in subchondral bone of the femoral head and the severity of osteoarthritic changes of the hip joint and in relation to minimal width of the joint space. 32 samples of subchondral bone were collected from patients with hip osteoarthritis during total hip replacement. The content of TGF-β1 was measured with the use of enzyme-linked immunoassay (ELISA).
We found statistically significant correlation between the content of TGF-β1 in subchondral bone and the severity of osteoarthritic changes. The content of TGF-β1 was directly proportional to the severity of osteoarthritic changes assessed by the Kellgren-Lawrence classification. The mean content of TGF-β1 in patients with minimal changes of the hip joint, classified as type II was 0,86 pg/μg, in comparison to the mean content of TGF-β1 in patients with severe osteoarthritis changes of the hip joint (group IV) where it was 1,72 pg/μg.
The results confirm the mutual role of TGF-β1 in the development of osteoarthritis of the hip joint.




INFLUENCE OF DAILY PHISICAL ACTIVITY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMAN WITH COXARTHRIS

II Środkowo Europejski Kongres Osteoporozy i Osteoartrozy oraz XIV Zjazd Polskiego Towarzystwa Osteoartrologii i Polskiej Fundacji Osteoporozy, Kraków 11-13.10.2007
Streszczenia:
Ortopedia Traumatologia Rehabilitacja 2007, vol 9 (Suppl. 2), s182.

P37
INFLUENCE OF DAILY PHISICAL ACTIVITY ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMAN WITH COXARTHRISIS

Milenovic N.1, Devecerski G.2, Popovic B.1, Vasic B.1

1 Institute for Rheumatology, High School of Medicine, University of Novi Sad, Serbia
2 Clinic for Medical Rehabilitation, High School of Medicine, University of Novi Sad, Serbia

Key words: osteoporosis, coxarthrosis, physical activity, postmenopausal woman

Introduction
One of common problem in postmenopausal woman is problem with reduced Bone Mineral Density (BMD). This could be more outstanding in patient with coxarthrosis, in who special way of living, which was cause on nature disease, could produce many problems in daily activity and also leave patient physically less active.
Aim
The aim of study was to establish how daily physical activity influence on BMD in postmenopausal woman with coxarthrtosis.
Material and methods
We examined 80 post-menopausal women (age 40-80) who were in post-menopause more than 12 months. All patients had coxarthrosis which was verified and now in grade II and III of Kellgren & Lawrence radiographic scale. Analysis of BMD was performed with „Sahara” ultrasound osteodesitometry. We used scale Body Mass Index (BMI), National Health Center Statistic Criteria and self-evaluation of health by patients.
Results
Average body mass was 73.125 kg (55.5-97.1) and body height was 1.56 cm (1.45-1.67) which was indicated that our patient was globally short female. Average BMI was 29.843 kg/m2 (23.32-37.89) which indicate that we had overweight patient (around 50% of our patient were belong in group of overweight patient). In 60% of our patient menopause started before 45 years old, and our entire patient were in post-menopause more than 12 months. Estimated BMD was 0.353g/cm2 (0.176-0.779). Average T-score was -2.25 (-3.6 till -0.2) which was indicated on osteopenia, which was also be in correlation with value of Z-score -1.485 (-2.7 till -0.1). We could find any statistically significant correlation between period of starting menopause and value of T and Z score. We found statistically significant correlation (r=0.447: p=0.0048) between BMI and estimated BMD which indicated that patient with higher value of BMI could have better BMD, which is in aggregation with fact that underweight could be risk factor for osteoporosis. Evaluating daily physical activity, according to walking more that 5 km per day, we found that 70% of our patient did not walk more than 5 km per day, which may be cause of their basic disease, and we did not find significant influence on BMD and T or Z score but in group of patient who daily practice static exercises, which was around 60% of our patients, we found statistically significant correlation between daily exercise and BMD (r=0.445, p=0.039) and T score (r=0.429; p=0.049) which indicated positive influence on BMD.
Conclusion
Daily practice of static exercises patient with coxarthrosis could positively influenced on increase BMD and bettering state of their bone which reduced many complications which is connected with basic disease.




P37 CORTICOSTEROIDS THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS

III Środkowo Europejski Kongres Osteoporozy i Osteoartrozy oraz XV Zjazd Polskiego Towarzystwa Osteoartrologii i Polskiej Fundacji Osteoporozy, Kraków 24-26.09.2009
Streszczenia:
Ortopedia Traumatologia Rehabilitacja 2009, vol 11 (Suppl. 2), s:153-154.
 
 
P37
CORTICOSTEROIDS THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
 
Milenovic N.1, Popovic B.2, Vasic B.1
 
1 Special Hospital for Rheumatology Disease, Novi Sad, Serbia
2 Faculty of Medicine, University of Novi Sad, Serbia
 
Key words: Rheumatoid arthritis, glikocorticoides, therapy outcome
 
Introduction: Rheumatoid arthritis (RA) as autoimmune, inflammatory arthropathy required specific treatment which includes usage of glikocorticoides (GC).
Aim: The aim of study was to evaluate effect of GC therapy in patients with RA.
Material and methods: We examined 250 patients 57.26 years old (± 9.34 years), 77.67% was female patient, who suffered from RA 8.39 years (1-39 years), in 89.32% was RF positive RA.
Results: Patients used in 95.15% non-fluorides GC. Predominate form was oral application 57.29% (prednisone 41.75% and metilptrednisolon 15.54%), but in 33.98 was intramuscular application of metilprednisolon-acetat. Only 3.88% patients took combination. Stage or RA changes was classified with Stein-Brocker`s criteria and we found that 45.63% of our patients were in Grade 3 anatomical classification but 58.25% were in Grade 2 functional classification, but bettering functional capacity statistically significant correlated (r=0.2227, p=0.024) was GC application. Morning stiffness longer than 60 minutes had 54.37%. Serious adverse effect was not evidenced.
Conclusion: We can conclude that application of corticosteroids in treatment RA can be safe and beneficial for patient.